Observed Signal · Sep 21, 2026 · Market Signal · Source: Galderma · Impact: 4.5/5
Galderma begins trading in the Swiss Market Index, joining Switzerland's leading blue chip companies
Galderma begins trading in the Swiss Market Index, joining Switzerland's leading blue chip companies. Also: Galderma's Restylane® Volyme™ demonstrates high effectiveness in Chinese patients; Galderma opens new U.S. and Latin America headquarters in Miami.
Track Galderma Signals & Market Shifts in Real-Time
Polaris7 autonomous intelligence agents track regulatory filings, primary sources, executive changes, and deal flow 24/7. Create your free Explorer workspace to monitor these entities.
Connected Companies & Entities
1 Entity mappedRelated Market Signals & Shifts
Recent verified developments and strategic activity across this market segment.
Galderma begins trading in the Swiss Market Index, joining Switzerland's leading blue chip companies
Galderma has been added to the Swiss Market Index (SMI), marking its inclusion among Switzerland's leading blue-chip companies. This is a major corporate milestone for the company.
EADV 2026: Galderma’s new data show sustained improvements with Nemluvio® (nemolizumab) for up to three years in patients with moderate-to-severe atopic dermatitis
Galderma's latest press release highlights new data presented at EADV 2026 showing sustained improvements with Nemluvio® (nemolizumab) for up to three years in patients with moderate-to-severe atopic dermatitis. Additionally, Galderma has begun trading in the Swiss Market Index, joining Switzerland's leading blue chip companies.
Roche and Ypsomed Stay Top in Swiss Reputation Ranking
Swissreputation Group and Pressrelations Schweiz analyzed nearly 90,000 reputation-relevant statements from about 4,000 Swiss online and print sources using an AI-supported method to evaluate media reputation for 40 pharma and medtech companies. The study measured presence (coverage and reach) and tonality (positive/negative reporting) and calculated a Reputation Score (0–100) for each company across six reputation dimensions. In Pharma & Biopharma, Roche ranks first (ahead of MSD, Novartis, Sandoz and AstraZeneca). In MedTech & Diagnostics, Ypsomed remains first (ahead of Medacta, Straumann Group, Alcon and Sonova). The study notes products/services, innovation and economic performance tended to improve media reputation, while workplace issues (layoffs, relocations) and ESG/legal problems harmed reputation. The article was published on 2026-08-13.
Track Real-Time Market Signals & Shifts
Set up custom watchlists to receive automated, evidence-grounded executive digests whenever material signals or shifts occur across your tracked landscape.